Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ: Low-dose Metronomic Topotecan and Pazopanib in Pediatric Solid Tumours
NCT02303028Phase 2Completed
- Sponsor
- SickKids
- Start
- Mar 2015
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan and pazopanib in solid tumor, sponsored by SickKids. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Started Mar 2015; status: completed.
02
Drugs
topotecanpazopanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02303028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303028.